Needham analyst David Saxon reiterated a Buy rating on CryoPort today and set a price target of $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Saxon has given his Buy rating due to a combination of factors including CryoPort’s impressive third-quarter revenue performance, which surpassed market expectations. The company’s success was largely driven by its Life Sciences Services segment, and management has subsequently increased its revenue guidance for 2025.
Additionally, there is potential for further revenue growth in 2026, as suggested by management’s commentary. CryoPort is also making strides towards achieving adjusted EBITDA profitability, with the possibility of reaching this milestone by the fourth quarter of 2025. These positive developments have led to an increased price target of $12, reinforcing the Buy rating.